CRSP Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—Forward 23.36
EPS (TTM)$-6.170.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$5.26BMid cap
Wall Street coverage
$83.52median target· current $59.60 (+40.1%)25 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 23.36
- PEG ratio
- -0.21
- P/B
- 2.88
- P/S (TTM)
- 1283.14
- EV/EBITDA
- 14.16
Profitability & growth
- ROE (TTM)
- -31.2%
- Operating margin
- -8933.0%
- Revenue growth YoY
- 68.6%
- Dividend yield
- —
- Beta
- 1.70
Last earnings
May 4, 2026 · Estimate $-1.23 · Reported $-1.28
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Crispr Therapeutics AG
Company profileCRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- BAARERSTRASSE 14, ZUG, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$5.26B
Shares outstanding$98.5M
52W high$78.48
52W low$43.23
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent